Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
192 participants
INTERVENTIONAL
2024-08-28
2027-08-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease
NCT05452304
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
NCT04877990
Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
NCT06053424
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
NCT01258205
A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
NCT01277666
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AZD7798
AZD7798
AZD7798
AZD7798
Placebo
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD7798
AZD7798
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of Crohn's disease established with verifiable clinical, AND at least one of imaging, endoscopic and/or histopathologic evidence.
3. Moderate to severe active Crohn's disease.
4. Ileal/ileocecal (L1), colonic (L2), or ileocolonic (L3) disease, as classified based on the localisation of active inflammation.
5. Capable of giving signed informed consent.
6. A history of at least one of:
1. Intolerance or inadequate response to conventional treatment (oral corticosteroid, azathioprine, 6-mercaptopurine, or methotrexate), biologics, or other approved advanced therapy (eg, JAK inhibitors) OR
2. Corticosteroid dependency (defined as inability to taper below budesonide 6 mg/day or prednisolone 10 mg/day equivalent dosing without recurrent active disease) for the treatment of Crohn's disease.
Exclusion Criteria
2. Known symptomatic strictures or bowel stenoses or strictures preventing passage of endoscope throughout the colon.
3. Any complications of Crohn's disease where surgery is anticipated or planned prior to end of study treatment.
4. Evidence of extensive prior gastrointestinal surgical interventions.
5. Within 3 months prior to screening endoscopy visit:
1. History of toxic megacolon
2. Diagnosis of peritonitis or need for treatment of peritonitis
3. Bowel perforation or evidence of obstruction.
6. All intrabdominal abscesses are excluded. Cutaneous and perianal/perirectal abscesses and fistulae are excluded unless adequately drained at least 4 weeks prior to screening endoscopy visit with no anticipation for surgery prior to end of study treatment.
7. Ongoing or expected nutritional dependency on total enteral or parenteral nutrition during study.
8. Evidence of an increased risk of colorectal cancer.
9. Symptomatic oral Crohn's disease within one year.
10. Any of the following treatments within the specified time period prior to screening endoscopy visit
1. An anti-TNF biologic within 8 weeks prior to screening endoscopy visit
2. Any biologic targeting immune response other than an anti-TNF within 12 weeks prior to screening endoscopy visit
3. Other advanced small molecule treatments for Crohn's disease within 4 weeks prior to screening endoscopy visit
4. Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, or tacrolimus (FK-506) within 4 weeks prior to screening endoscopy visit
5. Treatment with apheresis within 4 weeks prior to screening endoscopy visit
6. Administration of any live vaccine within 4 weeks prior to screening endoscopy visit to end of study
7. Faecal microbiota transplantation within 4 weeks prior to screening endoscopy visit
8. Lymphocyte-depleting treatment within 12 months prior to screening endoscopy visit
9. Any previous exposure to AZD7798.
11. Any changes in dosing of the following medications prior to screening endoscopy visit as outlined:
1. 5-aminosalicylates within 2 weeks
2. Oral corticosteroids within 2 weeks or stable doses of steroids exceeding the following dose equivalents:
(i) Systemic steroids \> 20 mg/day or prednisolone equivalent (ii) Locally targeted steroids exceeding maximum budesonide dose equivalent (9 mg/day) (c) Immunomodulators within 4 weeks (d) Antibiotic therapy for the treatment of Crohn's disease (e) Probiotics within 2 weeks.
12. Known or suspected history of chronic use of nonsteroidal anti-inflammatory drugs.
13. Evidence of recent or currently active infection, including use of IV or oral antibiotics for documented infection within 30 days prior to screening endoscopy visit.
14. Evidence of chronic HBV or HCV.
15. History of TB (active or latent) unless an appropriate course of treatment has been completed.
16. Positive diagnostic TB test at screening.
17. History of serious opportunistic infection within 12 months prior to screening endoscopy visit.
18. CMV colitis within previous 12 months prior to screening endoscopy visit.
19. Positive C. difficile toxin stool test at screening.
20. Symptomatic herpes zoster infection within 3 months prior to screening endoscopy.
21. Any identified immunodeficiency.
22. Abnormal laboratory results at screening suggesting participation may be unsafe, which will prevent the patient from completing the study, or will interfere with the interpretation of the study results.
23. Reproduction:
1. Pregnant and breastfeeding patients, or those planning to breastfeed during the study
2. FOCBP unless completely abstinent or using a highly effective contraception and barrier method of contraception.
24. Prolonged QTcF interval.
25. Clinically significant cardiovascular conditions.
26. Current malignancy or history of malignancy.
27. Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, haematological disease, hepatic disease, renal disease, gastrointestinal disease or other major disease other than active Crohn's disease.
28. Current enrolment in another interventional study or treatment with any investigational drug within 4 months prior to screening endoscopy visit.
29. Unstable lifestyle factors.
30. Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
31. Investigator concerns regarding patient's willingness and ability to attend all study visits, comply with the study procedures, read in order to complete questionnaires, or to complete the study period
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Phoenix, Arizona, United States
Research Site
Escondido, California, United States
Research Site
La Jolla, California, United States
Research Site
Victorville, California, United States
Research Site
Hamden, Connecticut, United States
Research Site
Orlando, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Idaho Falls, Idaho, United States
Research Site
Chicago, Illinois, United States
Research Site
Kansas City, Kansas, United States
Research Site
Ann Arbor, Michigan, United States
Research Site
Clinton Township, Michigan, United States
Research Site
Liberty, Missouri, United States
Research Site
St Louis, Missouri, United States
Research Site
Asheville, North Carolina, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Cleveland, Ohio, United States
Research Site
Uniontown, Pennsylvania, United States
Research Site
Dallas, Texas, United States
Research Site
Garland, Texas, United States
Research Site
Mansfield, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Buenos Aires, , Argentina
Research Site
CABA, , Argentina
Research Site
CABA, , Argentina
Research Site
Ciudad Autonoma de Bs As, , Argentina
Research Site
Ciudad de Buenos Aires, , Argentina
Research Site
Quilmes, , Argentina
Research Site
San Miguel de Tucumán, , Argentina
Research Site
Adelaide, , Australia
Research Site
Bedford Park, , Australia
Research Site
Box Hill, , Australia
Research Site
Epping, , Australia
Research Site
Fitzroy, , Australia
Research Site
Heidelberg, , Australia
Research Site
Liverpool, , Australia
Research Site
Melbourne, , Australia
Research Site
Parkville, , Australia
Research Site
South Brisbane, , Australia
Research Site
Wollongong, , Australia
Research Site
Klagenfurt, , Austria
Research Site
Vienna, , Austria
Research Site
Aalst, , Belgium
Research Site
Ghent, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Campinas, , Brazil
Research Site
Curitiba, , Brazil
Research Site
Jaú, , Brazil
Research Site
Porto Alegre, , Brazil
Research Site
Santo André, , Brazil
Research Site
São José do Rio Preto, , Brazil
Research Site
São Paulo, , Brazil
Research Site
São Paulo, , Brazil
Research Site
Gorna Oryahovitsa, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Lethbridge, Alberta, Canada
Research Site
Vaughan, Ontario, Canada
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Santiago, , Chile
Research Site
Talcahuano, , Chile
Research Site
Viña del Mar, , Chile
Research Site
Beijing, , China
Research Site
Chengdu, , China
Research Site
Guangzhou, , China
Research Site
Guangzhou, , China
Research Site
Hangzhou, , China
Research Site
Nanchang, , China
Research Site
Nanjing, , China
Research Site
Wuhan, , China
Research Site
Osijek, , Croatia
Research Site
Rijeka, , Croatia
Research Site
Zagreb, , Croatia
Research Site
Zagreb, , Croatia
Research Site
Amiens, , France
Research Site
Lille, , France
Research Site
Montpellier, , France
Research Site
Pierre-Bénite, , France
Research Site
Vandœuvre-lès-Nancy, , France
Research Site
Berlin, , Germany
Research Site
Frankfurt, , Germany
Research Site
Halle, , Germany
Research Site
Jena, , Germany
Research Site
Kiel, , Germany
Research Site
Potsdam, , Germany
Research Site
Ulm, , Germany
Research Site
Békéscsaba, , Hungary
Research Site
Budapest, , Hungary
Research Site
Gyöngyös, , Hungary
Research Site
Florence, , Italy
Research Site
Milan, , Italy
Research Site
Milan, , Italy
Research Site
Roma, , Italy
Research Site
Roma, , Italy
Research Site
Rome, , Italy
Research Site
Asahikawa-shi, , Japan
Research Site
Chiba, , Japan
Research Site
Hamamatsu, , Japan
Research Site
Hirosaki-shi, , Japan
Research Site
Hiroshima, , Japan
Research Site
Kamakura-shi, , Japan
Research Site
Kashiwa-shi, , Japan
Research Site
Kure-shi, , Japan
Research Site
Minatoku, , Japan
Research Site
Morioka, , Japan
Research Site
Nagasaki, , Japan
Research Site
Nagoya, , Japan
Research Site
Osaka, , Japan
Research Site
Sakura-shi, , Japan
Research Site
Sapporo, , Japan
Research Site
Sendai, , Japan
Research Site
Shinjuku-ku, , Japan
Research Site
Johor Bahru, , Malaysia
Research Site
Kota Bharu, , Malaysia
Research Site
Kota Kinabalu, , Malaysia
Research Site
Kuala Lumpur, , Malaysia
Research Site
Kuching, , Malaysia
Research Site
Durango, , Mexico
Research Site
Mexico City, , Mexico
Research Site
Mexico City, , Mexico
Research Site
Mérida, , Mexico
Research Site
México, , Mexico
Research Site
Tlajomulco de Zúñiga, , Mexico
Research Site
Veracruz, , Mexico
Research Site
Amsterdam, , Netherlands
Research Site
Nijmegen, , Netherlands
Research Site
Tilburg, , Netherlands
Research Site
Bydgoszcz, , Poland
Research Site
Chojnice, , Poland
Research Site
Krakow, , Poland
Research Site
Krakow, , Poland
Research Site
Lublin, , Poland
Research Site
Poznan, , Poland
Research Site
Poznan, , Poland
Research Site
Poznan, , Poland
Research Site
Sopot, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Wroclaw, , Poland
Research Site
Wroclaw, , Poland
Research Site
Bucharest, , Romania
Research Site
Bucharest, , Romania
Research Site
Bucharest, , Romania
Research Site
Cluj-Napoca, , Romania
Research Site
Timișoara, , Romania
Research Site
Košice, , Slovakia
Research Site
Nitra, , Slovakia
Research Site
Prešov, , Slovakia
Research Site
Trnava, , Slovakia
Research Site
Assagay, , South Africa
Research Site
Cape Town, , South Africa
Research Site
Milnerton, , South Africa
Research Site
Plumstead, , South Africa
Research Site
Alicante, , Spain
Research Site
Barcelona, , Spain
Research Site
Las Palmas de Gran Canaria, , Spain
Research Site
Madrid, , Spain
Research Site
Seville, , Spain
Research Site
Linköping, , Sweden
Research Site
Stockholm, , Sweden
Research Site
Kaohsiung City, , Taiwan
Research Site
New Taipei City, , Taiwan
Research Site
Taichung, , Taiwan
Research Site
Taipei, , Taiwan
Research Site
Taoyuan District, , Taiwan
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Ankara, , Turkey (Türkiye)
Research Site
Antalya, , Turkey (Türkiye)
Research Site
Bursa, , Turkey (Türkiye)
Research Site
Istanbul, , Turkey (Türkiye)
Research Site
Izmir, , Turkey (Türkiye)
Research Site
İzmit, , Turkey (Türkiye)
Research Site
Malatya, , Turkey (Türkiye)
Research Site
Chernivtsі, , Ukraine
Research Site
Kiev, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Kyiv, , Ukraine
Research Site
Ternopil, , Ukraine
Research Site
Vinnytsia, , Ukraine
Research Site
Vinnytsia, , Ukraine
Research Site
Hanoi, , Vietnam
Research Site
Hà Nội, , Vietnam
Research Site
Ho Chi Minh City, , Vietnam
Research Site
Hồ Chí Minh, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D9690C00005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.